AbbVie has put I-Mab out of its misery. More than a year after scrapping a pair of clinical trials, the Big Pharma has cut its ties to the anti-CD47 antibody lemzoparlimab altogether and deprived ...
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...
I-Mab Biopharma’s plan to become a U.S.-focused biotech took a stride forward with the news that the company is divesting its China operations. As a result, the company’s work in China—which is ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I-MAB ( (IMAB)) just unveiled an ...
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab ...
Hosted on MSN
I-Mab tumbles after announcing new business model
I-Mab (NASDAQ:IMAB) shares fell ~14% on Friday after the cancer drug developer announced a new “hub-and-spoke” business model, under which it plans to seek a name change and a potential dual listing ...
I-Mab stock has surged in 2025 on strong early data for lead asset givastomig in gastric cancer, showing an 83% ORR. Givastomig's results outperformed approved therapies and competitors, fueling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback